ArticlePublisher preview availableLiterature Review

Could α-Klotho Unlock the Key Between Depression and Dementia in the Elderly: from Animal to Human Studies

Authors:
To read the full-text of this research, you can request a copy directly from the authors.

Abstract and Figures

α-Klotho is known for its aging-related functions and is associated with neurodegenerative diseases, accelerated aging, premature morbidity, and mortality. Recent literature suggests that α-Klotho is also involved in the regulation of mental functions, such as cognition and psychosis. While most of studies of α-Klotho are focusing on its anti-aging functions and protective role in dementia, increasing evidence showed many shared symptoms between depression and dementia, while depression has been proposed as the preclinical stage of dementia such as Alzheimer’s disease (AD). To see whether and how α-Klotho can be a key biological link between depression and dementia, in this review, we first gathered the evidence on biological distribution and function of α-Klotho in psychiatric functions from animal studies to human clinical investigations with a focus on the regulation of cognition and mood. Then, we discussed and highlighted the potential common underlying mechanisms of α-Klotho between psychiatric diseases and cognitive impairment. Finally, we hypothesized that α-Klotho might serve as a neurobiological link between depression and dementia through the regulation of oxidative stress and inflammation.
This content is subject to copyright. Terms and conditions apply.
Could α-Klotho Unlock the Key Between Depression and Dementia
in the Elderly: from Animal to Human Studies
Xiang Gao
1
&Yuhong Li
1
&Zuoli Sun
2
&Hong Xu
2
&Guangwei Ma
1
&Qi Deng
1
&Claire X. Zhang
1
&Rena Li
1,2
Received: 12 June 2020 / Accepted: 25 January 2021
#The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021
Abstract
α-Klotho is known for its aging-related functions and isassociatedwith neurodegenerative diseases, accelerated aging, premature
morbidity, and mortality. Recent literature suggests that α-Klotho is also involved in the regulation of mental functions, such as
cognition and psychosis. While most of studies of α-Klotho are focusing on its anti-aging functions and protective role in
dementia, increasing evidence showed many shared symptoms between depression and dementia, while depression has been
proposed as the preclinical stage of dementia such as Alzheimers disease (AD). To see whether and how α-Klotho can be a key
biological link between depression and dementia, in this review, we first gathered the evidence on biological distribution and
function of α-Klotho in psychiatric functions from animal studies to human clinical investigations with a focus on the regulation
of cognition and mood. Then, we discussed and highlighted the potential common underlying mechanisms of α-Klotho between
psychiatric diseases and cognitive impairment. Finally, we hypothesized that α-Klotho might serve as a neurobiological link
between depression and dementia through the regulation of oxidative stress and inflammation.
Keywords α-Klotho .Aging .Dementia .Depression
Introduction
The α-Klotho gene is located on human chromosome 13 and
contains five exons [1,2] and encodes a single-pass type I
transmembrane protein with three domains: a short intracellu-
lar domain (~60 amino acids), a transmembrane domain, and a
large extracellular domain (~950 amino acids). As an anti-
aging protein, α-Klotho is widely expressed throughout the
human tissues, and the brain is one of the organs with highest
expression [3]. A full-length α-Klotho protein (~140 kD) can
be substrates for several enzymes [4,5], and the cleaved ex-
tracellular domain (~130 kD) gets into the blood, urine, and
cerebrospinal fluid as a soluble α-Klotho protein [6,7]. While
the full-length membrane-bound α-Klotho is known as a co-
receptor for fibroblast growth factor-23 (FGF23) and plays a
role in regulating the excretion of phosphate and synthesis of
active vitamin D [810], the soluble α-Klotho acts as a hor-
monal factor as well as an enzyme in regulating growth factor
signaling [1113], oxidative stress [14], and ion channels and
transporters [1518].
α-Klotho plays a well-recognized anti-aging function in
both animal models and human studies. Mice with lower ex-
pression of α-Klotho gene show shortened life span and pre-
mature onset of age-related phenotypes [1], while overexpres-
sion of α-Klotho gene prolongs the life span [19].
Furthermore, human studies reveal that allelic variations in
α-Klotho gene are closely associated with longevity, as well
as the risk of aging-related health conditions, such as cardio-
vascular disease [20], glucose metabolism [21], bone mineral
density [22], renal stones [23], breast cancer [24], and cogni-
tive impairment [2527]. α-Klotho is also well studied in
Alzheimers disease (AD), the most common dementia in
the elderly [28], while few studies also proposed the potential
role of α-Klotho in the mood disorders [2931].
With strong clinical evidence showing that depression and
dementia often share common symptoms, depression might
be a preclinical stage of dementia. For example, 511% of
AD patients also suffer from depression [32], and individuals
with depression had higher risk of dementia [3336]. Studies
also reported a reduction of hippocampal volume in both
*Rena Li
renali@ccmu.edu.cn
1
Beijing Institute of Brain Disorders, Laboratory of Brain Disorders,
Ministry of Science and Technology, Collaborative Innovation
Center for Brain Disorders, Capital Medical University,
Beijing 100069, China
2
Beijing Key Laboratory of Mental Disorders, Beijing Anding
Hospital, Beijing 100088, China
https://doi.org/10.1007/s12035-021-02313-0
/ Published online: 1 February 2021
Molecular Neurobiology (2021) 58:2874–2885
Content courtesy of Springer Nature, terms of use apply. Rights reserved.
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
Introduction: Klotho and dipeptidyl peptidase-4 (DPP4) are two proteins that modulate inflammatory pathways. We investigated the association between circulating klotho and DPP4 activity and their relationship with inflammatory cytokines, miR-29a, and miR-195 in Alzheimer disease (AD). Methods: This study was conducted on 16 AD patients and 16 healthy age-matched controls. Plasma levels of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β, interleukin-6 (IL-6), klotho, and DPP4 were measured by enzyme-linked immunosorbent assay. Plasma expression of miR-29a and miR-195 were also measured and compared by a real-time polymerase chain reaction. Results: There was a significant increase in TNF-α (p=0.006), IL-1β (p=0.012), and IL-6 (p=0.012) levels in the AD subjects compared with controls. Also, we found a decrease in plasma levels of klotho and an increase in plasma levels of DPP4 in the AD group that was not significant compared with the controls. Lower expression of miR-29a (P=0.009) and higher expression of miR-195 (P=0.003) were observed in the AD group that was significant than controls. Further analysis showed a negative correlation between klotho and plasma levels of IL-6 (r=-0.58, p=0.01). Also, there was a positive correlation between plasma DPP4 activity and TNF-α levels (r=0.50, P=0.04) and IL-1β (r=0.62, P=0.01). Likewise, plasma klotho concentration showed a negative correlation with the age of AD subjects (r=-0.56, P=0.02). Conclusion: TNF-α, IL-1β, and IL-6 are involved in AD pathophysiology, and dysregulation of DPP4 and klotho may be associated with the inflammatory response of AD. Down-regulation of miR-29a and up-regulation of miR‑195 indicated the role of miRNAs in the AD process.
Article
Full-text available
It is broadly acknowledged that the onset of dementia in Alzheimer’s disease (AD) may be modifiable by the management of risk factors. While several recent guidelines and multidomain intervention trials on prevention of cognitive decline address lifestyle factors and risk diseases, such as hypertension and diabetes, a special reference to the established risk factor of depression or depressive symptoms is systematically lacking. In this article we review epidemiological studies and biological mechanisms linking depression with AD and cognitive decline. We also emphasize the effects of antidepressive treatment on AD pathology including the molecular effects of antidepressants on neurogenesis, amyloid burden, tau pathology, and inflammation. We advocate moving depression and depressive symptoms into the focus of prevention of cognitive decline and dementia. We constitute that early treatment of depressive symptoms may impact on the disease course of AD and affect the risk of developing dementia and we propose the need for clinical trials.
Article
Full-text available
Decrease in soluble anti-aging Klotho protein levels is associated to cardiovascular disease (CVD). Diverse studies have shown a bidirectional relationship between Klotho and inflammation, a risk factor for the development of CVD. In this work we aimed to evaluate the association between Klotho and inflammatory cytokines levels in the context of human CVD.The study included 110 patients with established CVD and preserved renal function, and a control group of 22 individuals without previous history of cardiovascular events. Serum Klotho and IL10 levels were significantly lower in the CVD group. Inflammatory status, marked by the TNFα/IL10 ratio and the C-reactive protein (CRP) levels, was significantly increased in the group of patients with established CVD. Soluble Klotho levels were directly correlated with eGFR (r=0.217) and IL10 (r=0.209) and inversely correlated with age (r=-0.261), CRP (r=-0.203), and TNFα/IL10 (r=-0.219). This association with TNFα/IL10 remained significant in age-matched subgroups. Multiple logistic regression analysis showed that age, smoking and the neutrophil-to-lymphocyte ratio (NLR) constituted risk factors for the presence of CVD, while Klotho was a protective factor.In conclusion, in patients with established CVD, the reduction in soluble Klotho is associated with a pro-inflammatory status marked by lower IL10 concentrations and higher TNFα/IL10 ratio and CRP levels.
Article
Full-text available
Negative thinking is prominent in major depressive disorder (MDD). Cognitive models propose that negative thinking influences the hypothalamus-pituitary-adrenal axis and cortisol release. Oxytocin is also linked to MDD, social and affective processing, and stress buffering. Little research has examined direct relationships between negative cognitions, cortisol, and oxytocin.Methods Sixty-one unmedicated participants meeting DSM-5 criteria for MDD and 60 healthy controls completed measures of psychopathology, stress, and cognitions. Plasma samples were analyzed for cortisol and oxytocin. Between-group analyses of variance were conducted along with correlational, regression and mediation analyses.ResultsDepressed participants reported greater frequency and believability of negative thoughts than controls. Cortisol levels were positively, and oxytocin inversely, correlated with negative thinking. Cortisol and negative thinking accounted for unique variance in depression, and the relationship between stress and cortisol depended on the extent of negative cognitions.Conclusions The results support long-standing cognitive models which propose that negative thoughts are important in the relationship between stress and cortisol levels.
Article
Full-text available
This study investigated the association between depressive symptoms and cognitive function according to four different trajectories of depressive symptoms in the late middle-aged and older South Korean population. Panel data from the Korean Longitudinal Study of Ageing were analyzed. We used latent class trajectory models to identify four trajectories of depressive symptoms. We performed linear mixed-effects regression analysis to assess associations between depressive-symptom trajectories and MMSE scores. Of 4,374 participants, 18.4%, 4.9%, 55.2%, and 21.5% were classified as having a low, increasing, moderate declining, and high depressive-symptom trajectory, respectively. Individuals with an increasing trajectory (β = −0.729, P ≤ 0.001), moderate trajectory (β = −0.278, P = 0.003), and high trajectory (β = −1.605, P ≤ 0.001) had lower MMSE scores compared with those in the low trajectory group. These relationships were particularly strong among women; individuals who were physically inactive; those who were separated, divorced, or single; and those with hypertension or cerebrovascular disease. Each trajectory group for depressive symptoms was associated with cognitive decline. Moreover, female, physically inactive, and single individuals, as well as those with hypertension and cerebrovascular disease should be particularly mindful of their mental and physical health to prevent cognitive decline.
Article
Full-text available
Klotho is a humoral factor with pleiotropic effects. Most notably, Klotho deficiency is associated with a phenotype comprising organ manifestations accompanying aging including atherosclerosis and cognitive impairment. Research on the role of Klotho in affective disorder is scarce, which is surprising in light of the fact that depression is associated with accelerated cellular aging as well as aging-related phenotypes and comorbidity observed in Klotho deficiency. Soluble α-Klotho (sKlotho) serum levels in patients with a major depressive episode and either undergoing electroconvulsive therapy (n = 16) or a monotherapy with an antidepressant (n = 37) were investigated. We measured the sKlotho serum levels in those patients before and after treatment and compared the baseline levels with those of age-matched healthy controls (n = 39). No group differences were found between the baseline sKlotho levels of patients and controls (573.5 pg/ml vs. 563.8 pg/ml; p = 0.80) and between pre- and post-treatment in the patients with depression (563.8 pg/ml vs. 561.8 pg/ml; p = 0.15), when treated either with electroconvulsive therapy or antidepressant. The major limitation of our study might be that peripheral material such as serum might not reliably reflect processes in the central nervous system. In sum, this first study on peripheral sKlotho levels in a clinical sample cannot confirm a global Klotho dysregulation in depression as it has been already suggested by others. Nonetheless, further preclinical and clinical studies on the involvement of Klotho in affective disorders should be carried out.
Article
Background Previous evidence indicates late-onset depression or depression with greater severity are associated with subsequent risk of dementia or Alzheimer's disease (AD). However, whether treatment-resistant depression is associated with such risks remain elusive. Methods Using the Taiwan Nationwide Health Insurance Research Database, 3,345 patients with newly-diagnosed major depressive disorder (MDD) and 13,380 well-matched controls were enrolled between 2002 and 2004. MDD patients were stratified according to their treatment response to adequate antidepressant trials, and all participants were followed up until the end of 2013. Those who developed dementia and AD were identified. Results MDD patients were more likely to develop dementia and AD than controls. Difficult-to-treat patients (i.e., DTT; those who failed to respond to at least two adequate antidepressant trials) had the highest risk of developing dementia (hazard ratio [HR] = 5.19) and AD (HR 4.44), whereas easy-to-treat patients (i.e., ETT-1; those who had no prescription of antidepressants) had the lowest risk of developing dementia (HR 2.37) and AD (HR 2.59) compared with controls. Subsequent analysis demonstrated that only among patients with late-onset depression (age > 65 years), DTT patients consistently showed higher risks and faster development of dementia (HR 6.64, mean: 1.45yr) and AD (HR 4.97, mean: 1.67yr) than did ETT-1 patients and controls. Limitations Subjects who have not received medical examination were not included as diagnosis were determined by ICD codes. Also, longer follow-up period might be needed for the younger group. Conclusions Late-onset treatment-resistant depression is associated with an elevated risk of dementia and AD.
Article
The apolipoprotein E ε4 (APOE4) allele is the strongest genetic risk factor for Alzheimer disease (AD), the most common neurodegenerative condition. Unfortunately, APOE4 is not rare. Approximately 23% of the US population carries an allele. One copy increases risk of developing AD by 3-fold; 2 copies increases it by more than 12-fold. The APOE4 allele shortens the time to disease onset and reduces survival¹,2 in both sporadic and familial AD. Beyond AD, APOE4 increases the likelihood of cognitive decline in patients with other neurologic disorders,³ elderly people who are clinically normal,⁴ and even patients with head trauma as putatively mild as heading a ball in soccer.⁵ Neuroanatomic differences with APOE4 have been detected in AD-relevant brain regions in adolescence⁶ and as early as infanthood.⁷ Remarkably—despite the lifelong influences of APOE4—not all who carry the allele are fated for AD.
Article
Question: Does Klotho-VS heterozygosity protect against Alzheimer disease (AD) in individuals who carry APOE4? Findings: In this study, associations were evaluated across 22 AD cohorts (n = 20 928), 3 longitudinal cohorts (n = 3008), and 4 cohorts collecting β-amyloid measurements (cerebrospinal fluid, n = 556; brain, n = 251). In individuals who carry APOE4, Klotho-VS heterozygosity was associated with reduced AD risk and more favorable β-amyloid profiles in the brain and cerebrospinal fluid of older control participants. Klotho-VS heterozygosity was also associated with reduced AD conversion risk in individuals who carry APOE4. Meaning: Pathways associated with KL merit exploration for novel AD drug targets, and the KL-VS genotype should be considered in conjunction with APOE genotype to refine prediction models used in clinical trial enrichment.
Article
Hyalinosis is a vascular lesion affecting the renal vasculature and contributing to ageing-related renal function decline. We assessed whether arteriolar hyalinosis is caused by Klotho deficiency - a state known to induce both renal and vascular phenotypes associated with ageing. Histochemistry was used to assess hyalinosis in Klotho-/- kidneys, compared to Klotho+/- and wild-type littermates. Immunohistochemistry was used to investigate vascular lesion composition and the different layers of the vascular wall. Finally, spironolactone was used to inhibit calcification in kl/kl mice and vascular lesions were characterized in the kidney. Arteriolar hyalinosis was detected in Klotho-/- mice, which was present up to the afferent arterioles. Hyalinosis was accompanied by loss of α-smooth muscle actin expression, while the endothelial lining was mostly intact. Hyalinous lesions were positive for IgM and iC3b/c/d, indicating subendothelial leakage of plasma proteins. The presence of extracellular matrix proteins suggested increased production by smooth muscle cells. Finally, in Klotho-/- mice with marked vascular calcification, treatment with spironolactone allowed for replacement of calcification by hyalinosis. Klotho deficiency potentiates both endothelial hyperpermeability and smooth muscle cell de-differentiation. Absent a calcification-inducing stimulus, smooth muscle cells assume a synthetic phenotype in response to subendothelial leakage of plasma proteins. In the kidney, this results in arteriolar hyalinosis, which contributes to the decline in renal function. Klotho may play a role in preventing ageing-related arteriolar hyalinosis.